Wednesday, July 8, 2026

Patent intelligence · US

US 12049487

Universal chimeric antigen receptor T-cell preparation technique

granted A61KA61K2239/38A61K2239/48A61K40/11
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 18
Applicant portfolio 34
Patent details — US 12049487
Jurisdiction
US
Status
granted
Grant date
Jul 30, 2024
Expiration
Jul 25, 2044
Claims
10
CPC classes
A61K, A61K2239/38, A61K2239/48, A61K40/11
View on Google Patents ↗

Quick answer

US 12049487 (Universal chimeric antigen receptor T-cell preparation technique) is held by GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD.. Status: granted. Granted Jul 30, 2024. Expires Jul 25, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
10
CPC classes
A61K, A61K2239/38, A61K2239/48, A61K40/11, A61K40/22, A61K40/31

More from GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD.

Related pharmaceutical patents in our USPTO index.

  1. US 12414943

    Nimodipine parenteral administration

    Grace Therapeutics U.S., Inc. · Expires Sep 11, 2045

    granted
  2. US 11840575

    Engineered immune cells targeting BCMA and their uses thereof

    GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD. · Expires Dec 7, 2043

    granted
  3. US 11484501

    Mechanochemical activated dry amorphisation by milling equilibrium between ap mesoporous silica

    Grace GmbH · Expires Oct 27, 2042

    granted
  4. US 11478424

    Mechanochemcial activated dry amorphisation by milling equilibrium between AP mesoporous silica

    Grace GmbH · Expires Oct 20, 2042

    granted
  5. US 11478420

    Vaginal probiotic products and related processes

    Grace Procurements LLC · Expires Oct 20, 2042

    granted
  6. US 11291672

    Betamethasone oral spray formulation and method of use to treat ataxia

    GRACE THERAPEUTICS INC. · Expires Mar 31, 2042

    granted
  7. US 11052029

    Cation compatible metal oxides and oral care compositions containing the metal oxides

    W.R. Grace & Co.-Conn. · Expires Jul 1, 2041

    granted

Frequently asked questions

What is US patent 12049487?

US 12049487 (Universal chimeric antigen receptor T-cell preparation technique) is held by GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD.. Status: granted. Granted Jul 30, 2024. Expires Jul 25, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12049487?

GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 34 pharmaceutical patents for this assignee.

When does US 12049487 expire?

Our index shows an expiration date of Jul 25, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.